Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
54 studies found for:    FA2H
Show Display Options
Rank Status Study
1 Recruiting Stress Management for Cancer Patients: How Well Does it Work? (C2H-D)
Conditions: Mood;   Stress, Psychological
Intervention: Behavioral: From Cancer to Health (C2H-D)
2 Completed Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: Cetuximab;   Procedure: Liver resection;   Drug: Cetuximab and FOLFIRI;   Drug: Cetuximab and FOLFOX
3 Completed
Has Results
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
Condition: Hepatitis C
Interventions: Drug: TMC435;   Drug: Ribavirin (R);   Drug: PegIFNα-2a (P);   Drug: Placebo
4 Recruiting TR-701 FA vs Linezolid for the Treatment of Nosocomial Pneumonia
Condition: Pneumonia
Interventions: Drug: TR-701 FA IV;   Drug: Linezolid
5 Unknown  Involvement of Nervous System in Muscle Weakness in COPD Patients
Condition: Chronic Obstructive Pulmonary Disease
6 Recruiting Chemoradiation or Brachytherapy for Rectal Cancer
Condition: Rectal Cancer
Interventions: Radiation: Endo-HDR (if randomized to this arm);   Drug: capecitabine and IMRT (if randomized to this arm);   Radiation: IMRT (intensity modulated radiation therapy);   Drug: FOLFOX6;   Procedure: Surgery
7 Recruiting Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
Condition: Colorectal Cancer
Interventions: Drug: Cetuximab;   Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Oxaliplatin;   Drug: 5-FU;   Drug: Folinic Acid
8 Active, not recruiting A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
Condition: Atopic Dermatitis
9 Terminated Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
Condition: Exacerbation of Protein Losing Enteropathy
Interventions: Drug: ODSH at 0.125 mg/kg/h;   Drug: ODSH at 0.375 mg/kg/h;   Drug: ODSH at 0.250 mg/kg/h
10 Active, not recruiting Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes
Conditions: Anemia;   Intrauterine Growth Retardation;   Preterm Delivery;   Iron Deficiency
Interventions: Dietary Supplement: Multiple Micronutrient;   Dietary Supplement: Iron and Folic Acid;   Dietary Supplement: Folic Acid
11 Completed A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
Conditions: Colon Cancer;   Rectal Cancer
Interventions: Biological: IMC-1121B;   Biological: IMC-18F1;   Drug: mFOLFOX-6
12 Completed
Has Results
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
Condition: Colorectal Carcinoma
Interventions: Biological: IMC-1121B (ramucirumab);   Drug: Oxaliplatin;   Drug: Folinic acid;   Drug: 5-FU
13 Completed A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
Condition: Advanced Gastric Cancer
Intervention: Drug: mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )
14 Recruiting PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA
Condition: Measure of Uptake of XTRA in the Brain.
Intervention: Radiation: Positron Emission Tomagraphy (PET) Imaging
15 Completed Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects
Conditions: Dementia;   Alzheimer Disease
Intervention: Other: Neuroimaging
16 Completed Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
Conditions: Gastrointestinal Neoplasms;   Neoplasm Metastasis
Interventions: Drug: Mitomycin C;   Drug: 5-FU;   Drug: Folinic acid
17 Recruiting Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Maintenance Chemotherapy;   Drug: Panitumumab (Within maintenance phase);   Drug: mFOLFOX6 (Within re-induction phase);   Drug: Panitumumab (Within re-induction phase)
18 Active, not recruiting To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
Condition: Macular Edema (ME)
Interventions: Other: Sham control;   Drug: Ranibizumab
19 Terminated Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
Interventions: Procedure: CD34 selected haploidentical PBSCT;   Drug: Fludarabine;   Biological: T cell infusion;   Biological: Campath 1h;   Biological: anti-CD45
20 Recruiting Assess the Efficacy/Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Choroidal Neovascularization.
Condition: Choroidal Neovascularization (CNV)
Interventions: Drug: Ranibizumab;   Other: Sham control

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years